Related Experiment Videos
[Use of ciprofloxacin in children with mucoviscidosis]
Insights
Ciprofloxacin effectively treated children with mucoviscidosis, showing positive effects within 10-14 days. This antibiotic demonstrated a faster clinical remission in inpatients and a longer remission period in outpatients compared to other treatments.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and therapeutics
Background:
- Mucoviscidosis (cystic fibrosis) is a genetic disorder requiring long-term management of respiratory infections.
- Antibiotic resistance and treatment efficacy are critical concerns in cystic fibrosis care.
Purpose of the Study:
- To evaluate the efficacy and clinical outcomes of ciprofloxacin in pediatric patients with mucoviscidosis over a three-year period.
- To compare the remission periods and adverse effects of ciprofloxacin with other antibiotic regimens.
Main Methods:
- A retrospective analysis of 139 children with mucoviscidosis treated with ciprofloxacin over three years.
- Administration of ciprofloxacin orally (25-50 mg/kg/day) or intravenously (10-23 mg/kg/day) for 14-42 days.
- Comparison of clinical remission rates and durations between ciprofloxacin and other antibiotics (cephalosporins, aminoglycosides).
Main Results:
- Positive therapeutic effects observed in nearly all patients within 10-14 days of initiating ciprofloxacin therapy.
- Inpatients receiving ciprofloxacin achieved clinical remission approximately 3 days earlier than those on other treatments.
- Outpatients treated with ciprofloxacin experienced an average remission period of 62 days, significantly longer than with gentamicin (35 days) or azlocillin (30 days).
Conclusions:
- Ciprofloxacin is an effective antibiotic for managing mucoviscidosis in children, offering rapid symptom improvement.
- The drug is associated with favorable remission periods, particularly in outpatient settings.
- Adverse reactions were reported in 8% of patients, indicating a generally good safety profile.
Abstract:
The efficacy of ciprofloxacin was estimated for the last 3 years in the treatment of 139 children with mucoviscidosis. The drug was mainly used under hospital conditions. In 119 cases ciprofloxacin was administered orally in a daily dose of 25 to 50 mg/kg divided into 2 portions. The treatment course was 14-42 days. In 20 cases ciprofloxacin was used intravenously in a daily dose of 10 to 23 mg/kg injected twice a day with an interval of 12 hours. The treatment course was 14-18 days. Ciprofloxacin was used either alone (exclusively in outpatients) or in combination with the 2nd or 3rd generation cephalosporins or aminoglycosides. The positive effect was practically stated in all the patients in 10-14 days from the therapy start. The clinical remission at the background of the ciprofloxacin therapy in the inpatients was observed 3 days earlier than that in the inpatients treated without the use of ciprofloxacin. The remission period in the outpatients averaged 62 days while in the cases treated with gentamicin it was 35 days and in the cases treated with azlocillin it was 30 days. The adverse reactions were recorded in 8 per cent of the patients.